We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+21.97%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.76B
AUM Growth
+$163M
Cap. Flow
-$58.5M
Cap. Flow %
-2.12%
Top 10 Hldgs %
29.44%
Holding
155
New
9
Increased
52
Reduced
20
Closed
11

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$21.9M
2
EHC icon
Encompass Health
EHC
+$17.3M
3
ALLK
Allakos
ALLK
+$16.6M
4
ELAN icon
Elanco Animal Health
ELAN
+$13.2M
5
ENTA icon
Enanta Pharmaceuticals
ENTA
+$9.27M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$26.1M
2
GILD icon
Gilead Sciences
GILD
+$25.9M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$24.1M
4
ACHC icon
Acadia Healthcare
ACHC
+$22.1M
5
NUVA
NuVasive, Inc.
NUVA
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 89.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
76
DELISTED
Zogenix, Inc.
ZGNX
$11.7M 0.42%
235,000
+9,000
+4% +$458K
A icon
77
Agilent Technologies
A
$41.2B
$11.6M 0.42%
164,100
+400
+0.2% +$26.5K
TVTX icon
78
Travere Therapeutics
TVTX
$5.78B
$11.5M 0.42%
400,000
– –
MRTX
79
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$11.3M 0.41%
240,000
– –
CHRS icon
80
Coherus Oncology
CHRS
$196M
$11.1M 0.4%
670,000
-20,000
-3% -$355K
ARDX icon
81
Ardelyx
ARDX
$997M
$11M 0.4%
2,525,557
– –
QTTB icon
82
Q32 Bio
QTTB
$464M
$10.7M 0.39%
26,111
– –
EXEL icon
83
Exelixis
EXEL
$13.4B
$10.5M 0.38%
595,000
– –
ADAP
84
DELISTED
Adaptimmune Therapeutics
ADAP
$10.2M 0.37%
750,000
– –
TBIO
85
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$10.1M 0.37%
1,009,179
-1,900
-0.2% -$22.1K
MRSN
86
DELISTED
Mersana Therapeutics
MRSN
$10M 0.36%
40,000
– –
BHVN
87
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$9.76M 0.35%
260,000
-137,500
-35% -$5.06M
MYOV
88
DELISTED
Myovant Sciences Ltd.
MYOV
$9.23M 0.33%
347,500
+52,400
+18% +$1.19M
APTX
89
DELISTED
Aptinyx Inc. Common Stock
APTX
$8.83M 0.32%
305,000
-35,000
-10% -$851K
ACHN
90
DELISTED
Achillion Pharmaceuticals
ACHN
$8.83M 0.32%
2,400,000
+50,000
+2% +$149K
SRGA
91
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$8.78M 0.32%
65,000
– –
PTLA
92
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$8.62M 0.31%
323,800
– –
ODT
93
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$8.45M 0.31%
435,500
+37,750
+9% +$770K
FPRX
94
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$8.32M 0.3%
598,000
+5,000
+0.8% +$74.4K
CLVS
95
DELISTED
Clovis Oncology, Inc.
CLVS
$7.96M 0.29%
271,100
+16,100
+6% +$623K
ENTA icon
96
Enanta Pharmaceuticals
ENTA
$400M
$7.91M 0.29%
+92,500
New +$9.27M
BLUE
97
DELISTED
bluebird bio
BLUE
$7.67M 0.28%
4,053
+579
+17% +$1.2M
KURA icon
98
Kura Oncology
KURA
$850M
$7.09M 0.26%
405,000
+5,000
+1% +$95.9K
SAGE
99
DELISTED
Sage Therapeutics
SAGE
$6.92M 0.25%
49,000
– –
ZLAB icon
100
Zai Lab
ZLAB
$2.62B
$6.82M 0.25%
350,000
+50,000
+17% +$1.08M
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Rock Springs Capital Management held 155 positions worth $2.76B, up 6.3% from $2.6B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management's Q3 2018 filing shows 9 new, 52 increased, 20 reduced and 11 closed positions. Its largest new stake was Allakos: 405,000 shares worth $18.2M. The largest sale was AbbVie, an estimated $26.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier.

  • Rock Springs Capital Management's largest Q3 2018 buy was Allakos: 405,000 shares worth $18.2M.
  • Rock Springs Capital Management added most to Boston Scientific in Q3 2018, an estimated $21.9M increase.
  • Rock Springs Capital Management's biggest Q3 2018 reduction was AbbVie, cutting an estimated $26.1M.
  • Rock Springs Capital Management fully exited Gilead Sciences in Q3 2018, selling an estimated $25.9M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $2.76B portfolio in Q3 2018.
  • Rock Springs Capital Management opened 9 new positions and closed 11 in Q3 2018.
  • Rock Springs Capital Management's portfolio value rose 6.3% quarter-over-quarter to $2.76B.

Based on Rock Springs Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.